Gland Pharma shareholding pattern

Who owns itSep 2026 quarter

Promoters45.75%−6.02 pts
Foreign investors (FII)10.36%+1.62 pts
Domestic institutions (DII)33.21%+2.77 pts
of which mutual funds29.52%+1.29 pts
of which insurance companies2.43%
Public10.66%

Per cent of all shares; change on the Jun 2026 quarter, in percentage points. As filed with the exchanges.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

GLAND₹3,049.00

Gland Pharma Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABAUROPHARMAPPLPHARMASYNGENEWOCKPHARMAASTERDMCOHANCELALPATHLABMcap ₹50,235 Cr
Holding % of Total Shares
12 Months Ending
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Q2 FY27
30/09/2026
Promoter & Group51.8351.8351.8351.8351.8351.8351.8351.8351.7745.75
FII / FPI6.884.475.046.907.397.917.587.308.7410.36
DII32.8335.3734.8033.2732.8532.6432.9833.3530.4433.21
Mutual Funds30.5332.8332.3731.1630.6730.1931.4231.7828.2329.52
Latest: 2026-09-30 · 25 quarters of history · click a row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.